BACKGROUND: The Step Study, a Phase IIb HIV vaccine proof of concept study, enrolled approximately 3000 persons in clade B regions. The Atlanta site sought to enroll a diverse population. This prospective cohort study examined key factors associated with participant enrollment. METHODS: We obtained participant information (eg, sociodemographic, medical) and followed outcomes from 2005 to 2007. Of the 810 potential "Step Study" participants, 340 cases were analyzed. RESULTS: The recruitment strategy generated strong interest among minorities with 37% eligible after prescreening, yet 25% of the minorities enrolled. However, the percentage of whites increased from 62% eligible (prescreened sample) to 75% enrolled. The regression model was significant with educational level being an enrollment predictor (P = 0.0023). Those with at least a bachelor's degree were more likely to enroll compared with those with a K-12 education or some college (odds ratio = 2.424, 95% confidence interval = 1.372 to 4.281, P < 0.01). White race was also a significant factor (odds ratio = 2.330; 95% confidence interval = 1.241 to 4.375, P < 0.01). No difference in enrollment was observed among recruitment approaches, Pearson chi (2) (n = 336) = 5.286, P = 0.07. CONCLUSIONS: The results from this study indicate that women, minorities, and those with lower educational attainment were less likely to enroll in an HIV vaccine efficacy study at our site. The findings highlight an important consideration on the role of health literacy to sustain participation of eligible minorities in HIV vaccine trials.
BACKGROUND: The Step Study, a Phase IIb HIV vaccine proof of concept study, enrolled approximately 3000 persons in clade B regions. The Atlanta site sought to enroll a diverse population. This prospective cohort study examined key factors associated with participant enrollment. METHODS: We obtained participant information (eg, sociodemographic, medical) and followed outcomes from 2005 to 2007. Of the 810 potential "Step Study" participants, 340 cases were analyzed. RESULTS: The recruitment strategy generated strong interest among minorities with 37% eligible after prescreening, yet 25% of the minorities enrolled. However, the percentage of whites increased from 62% eligible (prescreened sample) to 75% enrolled. The regression model was significant with educational level being an enrollment predictor (P = 0.0023). Those with at least a bachelor's degree were more likely to enroll compared with those with a K-12 education or some college (odds ratio = 2.424, 95% confidence interval = 1.372 to 4.281, P < 0.01). White race was also a significant factor (odds ratio = 2.330; 95% confidence interval = 1.241 to 4.375, P < 0.01). No difference in enrollment was observed among recruitment approaches, Pearson chi (2) (n = 336) = 5.286, P = 0.07. CONCLUSIONS: The results from this study indicate that women, minorities, and those with lower educational attainment were less likely to enroll in an HIV vaccine efficacy study at our site. The findings highlight an important consideration on the role of health literacy to sustain participation of eligible minorities in HIV vaccine trials.
Authors: Jacqueline M O'Connell; Robert S Hogg; Keith Chan; Steffanie A Strathdee; Nancy McLean; Steve L Martindale; Brian Willoughby; Robert Remis Journal: J Acquir Immune Defic Syndr Date: 2002-12-15 Impact factor: 3.731
Authors: Gaston Djomand; Joanna Katzman; Dante di Tommaso; Michael G Hudgens; George W Counts; Beryl A Koblin; Patrick S Sullivan Journal: Public Health Rep Date: 2005 Sep-Oct Impact factor: 2.792
Authors: H Irene Hall; Ruiguang Song; Philip Rhodes; Joseph Prejean; Qian An; Lisa M Lee; John Karon; Ron Brookmeyer; Edward H Kaplan; Matthew T McKenna; Robert S Janssen Journal: JAMA Date: 2008-08-06 Impact factor: 56.272
Authors: Chuen-Yen Lau; Edith M Swann; Sagri Singh; Zuhayr Kafaar; Helen I Meissner; James P Stansbury Journal: Vaccine Date: 2011-08-05 Impact factor: 3.641
Authors: Tanya M Ellman; Kellie Hawkins; Jorge Benitez; Ramon Negron; Steven Chang; Steven Palmer; Verna Robertson; Mary Ann Chiasson; Magdalena E Sobieszczyk Journal: Vaccine Date: 2015-10-11 Impact factor: 3.641
Authors: Wen You; Fabio A Almeida; Jamie M Zoellner; Jennie L Hill; Courtney A Pinard; Kacie C Allen; Russell E Glasgow; Laura A Linnan; Paul A Estabrooks Journal: BMC Public Health Date: 2011-09-20 Impact factor: 3.295